Hyalex Orthopaedics Receives FDA Approval of IDE Supplement, Expanding the Early Feasibility Study to a Pivotal Trial of Cutting-Edge Freestyle Knee Implant

Company Plans to Initiate Pivotal Study of Transformative Implant Technology Designed to Help Patients with Cartilage Damage and Early Osteoarthritis Regain an Active Lifestyle

LEXINGTON, Mass., May 20, 2025 /PRNewswire/ -- Hyalex Orthopaedics, a privately held medical device company developing joint preservation technologies based on the transformative HYALEX^® HYDROSURF materials platform, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Investigational Device Exemption (IDE) application for its cutting-edge Freestyle Knee Implant. This approval paves the way for Hyalex to expand its Early Feasibility Study (EFS) into a pivotal clinical trial of its novel knee implant technology, supporting the company's continued efforts to bring this next-generation orthopedic solution to patients in need.

Hyalex's Freestyle Knee Implant is designed to enable patients suffering from cartilage damage and early osteoarthritis of the femoral condyle(s) to regain an active lifestyle. The planned pivotal trial, which will be conducted at leading orthopedic centers across the United States and Europe, will evaluate the safety and effectiveness of the device in restoring mobility and improving patient outcomes. Study investigators intend to enroll a diverse patient population that currently has limited treatment options.

"This FDA approval validates the rigorous research and development behind our Freestyle Knee Implant and propels us into the next phase of clinical evaluation," said Carl Vause, chief executive officer of Hyalex. "We are committed to advancing orthopedic care by delivering innovative solutions that address the unmet needs of cartilage gap patients, which is estimated to represent a $2 billion market in the US alone."

The planned pivotal trial will build upon promising clinical results seen by surgeons who have been involved in Hyalex's EFS of the Freestyle Knee Implant, including the study's national principal investigator, Sabrina Strickland, M.D., of Hospital for Special Surgery.

"In our early clinical evaluations, the HYALEX Freestyle Knee Implant demonstrated exceptional promise in mimicking natural joint mechanics and helping patient's return to their active lifestyle," said Dr. Strickland. "The ability to help these patients, who have limited options today, could significantly impact the future treatment of chondral and osteochondral defects in the knee."

To learn more about the Freestyle EFS, please visit https://clinicaltrials.gov/study/NCT06368700.

About Hyalex Orthopaedics

Hyalex is a privately held medical device company headquartered in Lexington, MA, developing transformational joint preservation technologies for diseased and damaged joints. The HYALEX^® HYDROSURF materials platform is protected by more than 17 patents and trademarks worldwide. The HYALEX Freestyle Knee system has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration for a clinical trial in the United States.

For more information: www.hyalex.com

Contact Information:

Tim Brons
Vida Strategic Partners (media)
646-319-8981
[email protected]

SOURCE Hyalex Orthopaedics